Drugs / KB-GDT-01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06069570 | Nov 2023 → Oct 2025 overdue | metastatic carcinoma in the bone, non-small cell lung carcinoma | Kiromic BioPharma Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KB-GDT-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06069570 ↗ |
| Modality | Cell therapy | “KB-GDT-01, an allogeneic (cells from healthy donors) gamma delta T-cell product” NCT06069570 ↗ |
| Route | Intravenous | “administered intravenously (IV)” NCT06069570 ↗ |